Abstract
Respiratory syncytial virus (RSV) is a significant health issue. Nearly all children contract RSV by 3 years of age. This virus causes mild cold-like symptoms in older children and adults. However, in infants and toddlers, it causes serious lower respiratory tract infections. Recovery from RSV can be lengthy, and caring for an unwell child can become a burden for a family. Prevention plans for those children that are at highest risk have been helpful in reducing the incidence of RSV. The American Academy of Pediatrics outlines the use of Palivizumab as part of its RSV prevention guidelines.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
